Pain Therapeutics, Inc. (NASDAQ:PTIE) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 1,101,252 shares, a decline of 4.1% from the November 15th total of 1,147,759 shares. Approximately 35.6% of the shares of the stock are short sold. Based on an average daily volume of 49,621 shares, the days-to-cover ratio is presently 22.2 days.

Shares of Pain Therapeutics (PTIE) opened at $4.11 on Thursday. Pain Therapeutics has a 12-month low of $3.10 and a 12-month high of $9.31.

Pain Therapeutics (NASDAQ:PTIE) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) EPS for the quarter. equities research analysts anticipate that Pain Therapeutics will post -2.2 EPS for the current year.

A number of analysts have commented on PTIE shares. ValuEngine downgraded Pain Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Zacks Investment Research upgraded Pain Therapeutics from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research report on Tuesday, October 31st.

A hedge fund recently bought a new stake in Pain Therapeutics stock. Dimensional Fund Advisors LP acquired a new stake in Pain Therapeutics, Inc. (NASDAQ:PTIE) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 59,989 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Dimensional Fund Advisors LP owned approximately 0.91% of Pain Therapeutics as of its most recent SEC filing. 35.99% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with's FREE daily email newsletter.